<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26094">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767063</url>
  </required_header>
  <id_info>
    <org_study_id>P13/12_ACTIW</org_study_id>
    <nct_id>NCT02767063</nct_id>
  </id_info>
  <brief_title>Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)</brief_title>
  <acronym>ACTIW</acronym>
  <official_title>Candidate Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors in Chronic Phase-chronic Myelogenous Leukemia Patients in CCR Without Achieving a Deep Molecular Response: an Adaptative Trial Based on a Drop Loser Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be randomized in phase II trials to continue on the same TKI versus one of the
      alternative treatment approaches. If a patient is not eligible for one of the treatments, he
      (she) will be randomized between the options for which he (she) is eligible.

      The trial will start with current available treatment options (experimental arms). New
      available treatment options may be open at any times later on. Authorized TKIs are imatinib,
      nilotinib, dasatinib, bosutinib and ponatinib.

      For all options the treatment duration is for a minimum of 12 months and will be continued
      in the absence of adverse events following investigator decision. Each therapeutic option
      will be detailed in term of combination modalities, dose, dose adaptation, specific
      warnings, specific exclusion and inclusion criteria. The decision to introduce a new option
      will depend on the general pace of recruitment and on the assessment of the potential
      efficacy and safety of the new treatment, and will be implemented after scientific review by
      a protocol amendment.

      Primary objective:

      A. To select molecules in combination or sequentially with imatinib, nilotinib, dasatinib,
      bosutinib or ponatinib potentially able to produce a 25% increase in the Cumulative
      Incidence of MR4.5 as compare to control.

      Secondary objectives:

      A. To determine the safety of selected therapies

      B. To determine the rate of MR4 by 12, 24, 36, 48 months in experimental and control arms

      C. To determine the rates of MR4.5 by 24, 36, 48 months in experimental and control arms

      D. To determine the rate of undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies)
      by 12, 24, 36, 48 months in experimental and control arms

      E. To estimate treatment free remission (TFR) in patients eligible for discontinuation
      studies

      F. To investigate the relationship between biological activity and the clinical efficacy of
      the selected therapies

      G. To assess the effects of the treatments on the number and clonogenicity of CML stem cells
      and other biological markers of interest

      H. To estimate duration of response, progression-free survival, event free survival and
      overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomised to continue on TKI (same daily dose) versus one of the X
      alternative novel treatment approaches. If a patient is not eligible for one of the
      treatments, he will be randomised between the options for which he is eligible.

      All treatment options may be open at all times.

      The first available treatment arms will be:

        1. TKI alone same daily dose (control arm)

        2. TKI in combination with pioglitazone

      Planned treatment arms for the future may be :

        1. TKI in combination with pegylated interferon

        2. TKI in combination with arsenic trioxide

        3. TKI in combination with Homoharringtonine

        4. TKI in combination with anti-PD-L1 antibody

      For all options the treatment plan is for at least 12 months depending on each molecule
      tested.

      New treatment options will be introduced over time. The decision to introduce a new option
      will depend on the general pace of recruitment and the assessment of the potential efficacy
      and safety of the new treatment in this patient population, and will be implemented after
      scientific review by a protocol amendment.

      Protocol plan:

        1. Control arm (Imatinib, nilotinib, dasatinib, bosutinib or ponatinib):

           Daily dose and schedule identical to the daily dose and schedule administered during
           the last 3 months

        2. Pioglitazone arm TKI : Daily dose and schedule identical to the daily dose and schedule
           administered during the last 3 months

      PIOGLITAZONE (Actos®):

      30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in
      the absence of grade &gt;1 related AE.

      3. Other experimental arm TKI : Daily dose and schedule identical to the daily dose and
      schedule administered during the last 3 months

        -  Arsenic trioxide : to be determined after amendment

        -  Pegylated Interferon : to be determined after amendment

        -  Anti-PD-L1 antibody : to be determined after amendment

        -  Homoharringtonine : to be determined after amendment

        -  Drug X

        -  Drug Y

      After 12 Months :

      Continue TKI at the same daily dose. Continue experimental drug if indicated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of patients achieving a deep molecular response</measure>
    <time_frame>12 months</time_frame>
    <description>The cumulative incidence of patients achieving a deep molecular response defined by MR4.5 or deeper (BCR-ABLIS ≤ 0.0032 %) by 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 Months</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4.5 by 24months in experimental and control arms</measure>
    <time_frame>24 months</time_frame>
    <description>The cumulative rate of patients achieving MR4.5 by 24months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4.5 by 36 months in experimental and control arms</measure>
    <time_frame>36 months</time_frame>
    <description>The cumulative rate of patients achieving MR4.5 by 36 months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4.5 by 48 months in experimental and control arms</measure>
    <time_frame>48 months</time_frame>
    <description>The cumulative rate of patients achieving MR4.5 by 48months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4 by 12months in experimental and control arms</measure>
    <time_frame>12 months</time_frame>
    <description>The cumulative rate of patients achieving MR4 by 12,months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4 by 24 months in experimental and control arms</measure>
    <time_frame>24 months</time_frame>
    <description>The cumulative rate of patients achieving MR4 by 24 months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4 by 36 months in experimental and control arms</measure>
    <time_frame>36 months</time_frame>
    <description>The cumulative rate of patients achieving MR4 by 36 months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4 by 48 months in experimental and control arms</measure>
    <time_frame>48 months</time_frame>
    <description>The cumulative rate of patients achieving MR4 by 48 months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12months in experimental and control arms</measure>
    <time_frame>12 months</time_frame>
    <description>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 24months in experimental and control arms</measure>
    <time_frame>24 months</time_frame>
    <description>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 24, months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 36 months in experimental and control arms</measure>
    <time_frame>36 months</time_frame>
    <description>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 36 months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 48 months in experimental and control arms</measure>
    <time_frame>48 months</time_frame>
    <description>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 48 months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients in treatment free remission during follow-up</measure>
    <time_frame>48 months</time_frame>
    <description>The rate of patients in treatment free remission during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of CML- and normal-CFU in bone marrow by clonogenic assays and RTQ- PCR</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>48 months</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>48 months</time_frame>
    <description>duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event free survival</measure>
    <time_frame>48 months</time_frame>
    <description>event free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>48 months</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Leukemia, Myeloid, Chronic-Phase</condition>
  <arm_group>
    <arm_group_label>Experimental Arm_ACTOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
PIOGLITAZONE (Actos®):
30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade &gt;1 related AE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controled Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade &gt;1 related AE.</description>
    <arm_group_label>Experimental Arm_ACTOS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient aged 18y or more

          2. Signed informed consent

          3. Patient with Philadelphia chromosome positive chronic phase CML and M BCR-ABL1
             transcript positivity

          4. Treatment with imatinib, nilotinib, dasatinib, bosutinib or ponatinib for more than 2
             years overall

          5. No switch between tyrosine kinase inhibitors within the last 3 months

          6. No dose modification within the last 3 months

          7. Complete cytogenetic response or BCR-ABLIS ≤ 1%

          8. Detectable BCR-ABL1 with BCR-ABLIS &gt; 0.0032% (less than MR4.5)

          9. ECOG grade 0 to 2

         10. ASAT and ALAT ≤ 2.5 N

         11. Bilirubin in serum ≤ 2.5 N

         12. Women of childbearing potential must be using an adequate method of contraception

        Exclusion Criteria:

          1. Pregnant or lactating women,

          2. Participation in another clinical trial with any investigative drug within 30 days
             prior to study enrolment,

          3. Patient requiring anti-diabetic medication

          4. Prior history of hematopoietic stem cell transplantation (autologous or allogenic)

          5. Cardiovascular disease:

               -  Stage II to IV congestive heart failure (CHF) as determined by the New York
                  Heart Association (NYHA) classification system for heart failure.

               -  Myocardial infarction within the previous 6 months

               -  Symptomatic cardiac arrhythmia requiring treatment

          6. Grade III or IV fluid retention

          7. Known BCR-ABL kinase domain mutation

          8. CML patient not in chronic phase at diagnosis

          9. Individuals with an active malignancy

         10. Kown HIV-positivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe ROUSSELOT</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Versailles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laure MORISSET</last_name>
    <phone>003339239785</phone>
    <email>lmorisset@ch-versailles.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Martine GARDEMBAS</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine GARDEMBAS</last_name>
      <phone>02.41.35.44.75</phone>
      <email>MaGardembas@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pascale CONY.MAKHOUL</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale CONY.MAKHOUL</last_name>
      <phone>04.50.63.64.31</phone>
      <email>pconymakhoul@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thorsten BRAUN</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten BRAUN</last_name>
      <phone>01.48.95.54.58</phone>
      <email>Thorsten.braun@avc.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Etienne</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Etienne</last_name>
      <phone>05.56.33.04.76</phone>
      <email>G.Etienne@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ROY Lydia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rousselot</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Rousselot</last_name>
      <phone>01.39.63.89.09</phone>
      <email>phrousselot@ch-versailles.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>COITEUX Valérie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franck NICOLINI</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck NICOLINI</last_name>
      <phone>04.72.11.74.01</phone>
      <email>franck.nicolini@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut P Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CHARBONNIER Aude</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Viviane DUBRUILLE</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviane DUBRUILLE</last_name>
      <phone>02.40.08.32.71</phone>
      <email>Viviane.dubruille@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eric JOURDAN</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric JOURDAN</last_name>
      <phone>04.66.68.32.31</phone>
      <email>eric.jourdan@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital La Source</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BENBRAHIM Omar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Delphine REA _St louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine REA</last_name>
      <phone>01.42.49.96.49</phone>
      <email>delphine.rea@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Simona LAPUSAN_St Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona LAPUSAN</last_name>
      <phone>01.49.28.34.42</phone>
      <email>Simona.lapusan@sat.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cayssials</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Cayssials</last_name>
      <phone>: 05.49.44. 44.72</phone>
      <email>e.cayssials@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ESCOFFRE-BARBE Martine</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DARTIGEAS Caroline</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 19, 2016</lastchanged_date>
  <firstreceived_date>March 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Versailles</investigator_affiliation>
    <investigator_full_name>Philippe ROUSSELOT</investigator_full_name>
    <investigator_title>Clinical coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
